Serve or Swerve – what will Mervyn say?!

If you haven’t heard of him, you’ve been living under a rock somewhere! Prof. Mervyn Singer OBE, is a renowned Professor of Critical Care from the UK. He is one of the most animated speakers you will ever see, aside from Peter Brindley, JL Vincent! He will be talking at the Intensive Care Society’s SOA25 Congress in Birmingham from July 1-3, 2025.

Book here!

I took some wild guesses at what he would be talking about, and MIGHT have talked to him too…..

His topic, “A 40-year review of ICU evolution: The Very Good, the Good, and the Not-So-Good,” is going to be a fabulous insight into what our most esteemed Prof. thinks of decades of progress….well….potentially progress?!

Will Merve swerve, or serve though…and on what?

All the good?

There are the major breakthroughs since the 1980s that have transformed ICU care:

• Advancements in mechanical ventilation, such as the development of lung-protective strategies (e.g., low tidal volume ventilation from the ARDSNet trial in 2000), which drastically reduced mortality in acute respiratory distress syndrome (ARDS).
• He might also highlight the introduction of evidence-based protocols like the Surviving Sepsis Campaign guidelines, which standardized early goal-directed therapy and improved sepsis outcomes.

He may discuss incremental progress that has solidified ICU practices:

• This could involve the refinement of monitoring technologies, like advanced hemodynamic monitoring
• He might also touch on the growing emphasis on multidisciplinary care teams, including the integration of pharmacists and physiotherapists in the ICU, leading to better patient recovery and reduced complications.

All the bad?

The “Not-So-Good” will likely address persistent challenges and areas needing improvement, many of which may be considered as “Iatrogenic Harm”:

• ICU-acquired infections, such as ventilator-associated pneumonia, remain a significant problem despite better protocols.
• ICU delirium, which affects up to 80% of mechanically ventilated patients and is linked to long-term cognitive impairment, may crop up.
• Ventilator associated pneumonia
• Staffing shortages and burnout among ICU professionals, which have been exacerbated since the COVID-19 pandemic, may also raise their heads

What else?

Merv’s other thoughtful insights will probably emphasize the need for continued research:

• Personalized medicine in the ICU, such as using biomarkers to tailor treatments
• The importance of addressing long-term patient outcomes, like post-intensive care syndrome (PICS).

Let’s chat about the gritty topics!

Here’s the jump list!

1. ICU Infections
2. ICU delirium
3. Ventilator Associated Lung Injury
4. Sepsis
5. PICS
6. Outreach
7. MDT
8. Technology
9. Audit
10. Anarchy
11. Negative Studies
12. The Firm

1. ICU-acquired infections

These remain a significant challenge, despite progress in infection control.

• 2022 study using the MIMIC-IV database found that 17.1% of 16,808 septic ICU patients developed an ICU-acquired infection, leading to a 17.7% ICU mortality and 31.8% in-hospital mortality. Independent risk factors included common ICU interventions that, while life-saving, increase infection risk.
  • tracheostomy
  • central venous catheters
  • urinary catheters
  • mechanical ventilation
  • red blood cell transfusions

Merv might emphasize the need for stricter protocols, like those seen in the

• “Matching Michigan” initiative, which reduced catheter-related bloodstream infections through standardized care bundles. However, the study also suggests that while these infections increase short-term mortality, their impact on long-term survival may be less significant than previously thought, as a 2007 prospective cohort study found no difference in long-term mortality or quality of life between ICU survivors with and without such infections. So, perhaps it’s just about balancing aggressive infection prevention with the reality of ICU interventions, possibly advocating for innovations like antimicrobial coatings on catheters or AI-driven infection monitoring.

Of note, iatrogenic harm still persists, pointing to unintended consequences like the Clostridium difficile (C. diff) outbreak following the introduction of alcohol-based hand gels. While these gels reduced other infections, they were ineffective against C. diff spores, leading to a spike in cases—a reminder that new interventions can have unexpected downsides.

No Direct Causation of Increased Infections:

• Studies, such as a retrospective analysis by Knight et al. (2010), found no evidence that implementing hospital-wide ABHR policies directly increased C. difficile-associated diarrhea (CDAD) rates. However, they noted an increase in sepsis among CDAD patients, suggesting greater severity in affected cases, possibly due to other factors like patient acuity or hypervirulent strains (e.g., NAP1/027).
• The rise in C. difficile infections over the past two decades is more closely tied to factors like the emergence of hypervirulent strains (NAP1/027), increased antibiotic use (e.g., fluoroquinolones, cephalosporins), and aging patient populations, rather than hand gel use alone.

Hand Gel Limitations and Over-Reliance:

• ABHRs do not eliminate C. difficile spores, which can persist on hands and surfaces. In ICUs, where healthcare workers (HCWs) frequently use ABHRs for convenience and speed, over-reliance on gels instead of soap-and-water washing after caring for C. difficile patients may contribute to spore transmission. Studies show HCW hand contamination rates with C. difficile range from 0% to 59% after patient contact, highlighting the risk if proper hand hygiene protocols are not followed.
• A study emphasized that soap-and-water handwashing is essential after caring for C. difficile patients, as it physically removes spores. Interventions improving access to sinks (e.g., visible sink placement) have increased soap-and-water use and reduced ABHR reliance, correlating with better hand hygiene compliance in CDI cases.

ICU-Specific Factors:

• ICUs have higher C. difficile infection rates (8–10% of all CDI cases) due to patient risk factors like prolonged hospitalization, antibiotic exposure, and immunosuppression.
• During the COVID-19 pandemic, enhanced hand hygiene (including ABHR use) and restricted hospital referrals were associated with no significant increase in CDI incidence in some studies, suggesting that hand gels alone don’t drive rises when combined with other infection control measures. However, severe CDI cases increased during the second wave, possibly due to delayed diagnostics or reduced hospital access, not directly hand gel use.
• Environmental contamination in ICUs (e.g., spores on surfaces) and HCW hand carriage remain significant transmission routes. If ABHRs are used inappropriately in place of soap-and-water, spores may persist, indirectly contributing to infections.

Confounding Factors:

• The rise in CDI is multifactorial. Antibiotic stewardship failures, inadequate environmental cleaning, and lack of adherence to contact precautions (e.g., gloves, gowns) play larger roles than hand gel use.
• Patient hand hygiene is also underutilized. A study showed that improving patient hand hygiene with soap and water reduced CDI events, suggesting that focusing only on HCW hand gel use misses other transmission pathways.
• Some ICUs implementing antimicrobial stewardship programs (ASPs) saw no change in CDI rates, indicating that hand hygiene practices, including gel use, are just one piece of the puzzle.

2. ICU delirium

A pervasive issue affecting up to 80% of mechanically ventilated patients, with long-lasting effects on cognitive health. Why:

• Aging Population: Older patients, who are more susceptible to delirium due to comorbidities and cognitive vulnerabilities, are increasingly admitted to ICUs. Studies note age as a significant predisposing factor.

• Improved Detection: Validated tools like the Confusion Assessment Method for the ICU (CAM-ICU) and Intensive Care Delirium Screening Checklist (ICDSC) have increased recognition of delirium, revealing its high prevalence (up to 80% in some cohorts).

• Complex Interventions: Greater use of mechanical ventilation, sedatives (e.g., benzodiazepines), and polypharmacy in ICUs contributes to delirium risk. Benzodiazepines, for instance, are strongly linked to delirium in a dose-dependent manner.

• Underrecognition and Inconsistent Management: Despite guidelines recommending routine delirium screening, adherence is low globally (e.g., only 11.9% of Polish ICUs monitor delirium). Lack of staff training and standardized protocols exacerbates the issue.

• Impact of Pandemics: The COVID-19 pandemic worsened delirium incidence due to increased benzodiazepine use, restricted family visits, and reduced monitoring, highlighting systemic vulnerabilities.

• Long-Term Consequences: Growing evidence links ICU delirium to persistent cognitive impairment, with over 50% of survivors showing deficits akin to Alzheimer’s or traumatic brain injury one year post-ICU. This has heightened focus on delirium as a public health issue costing $4-16 billion annually in the U.S. alone.

A 2022 article on the future of ICU care highlights how the COVID-19 pandemic worsened delirium incidence due to increased benzodiazepine use, restricted family visitation, and staffing shortages—factors that disrupted non-pharmacological interventions like the ABCDEF bundle (Awakening and Breathing Coordination, Delirium monitoring, Early mobility, Family engagement). Mervyn may mention the over-reliance on sedation during the pandemic, pointing to studies showing that minimizing sedation and prioritizing early mobility can reduce delirium incidence. For instance, a 2023 study noted that daily mobilizations over 40 minutes improved functional outcomes at ICU discharge. However, Merv might caution against over-optimism, as bedside assessments like the Confusion Assessment Method for the ICU (CAM-ICU) remain the gold standard, and technological solutions need more validation.

Studies

Salluh et al. (2015) – Systematic Review and Meta-Analysis

• Source: The BMJ
• Findings: Analyzed 42 studies (16,595 patients) and found delirium in 31.8% of ICU patients. Delirium was associated with a 2.19 risk ratio for in-hospital mortality (95% CI 1.78-2.70). It also increased ICU and hospital length of stay and mechanical ventilation duration.
• Significance: Established delirium as a strong predictor of adverse short-term outcomes and emphasized the need for routine screening with tools like CAM-ICU.

Thein et al. (2020) – Meta-Analysis on Delirium-Associated Mortality

• Source: BMC Geriatrics
• Findings: Delirium increased all-cause mortality in hospitalized patients, with higher odds in ICU settings due to illness severity. No reduction in delirium-related mortality was observed over 30 years, indicating persistent challenges in management.
• Significance: Highlighted the unchanged mortality burden and called for improved detection and intervention strategies, noting only 40% of health professionals routinely screen for ICU delirium.

Wu et al. (2023) – Systematic Review and Meta-Analysis

• Source: Nursing in Critical Care
• Findings: Reported delirium prevalence of 32-80% in ICU patients. Identified 28 risk factors, with modifiable factors like pain, sedation, and sleep deprivation being critical. Non-modifiable factors included age and dementia.
• Significance: Provided comprehensive data on risk factors, supporting early detection models like PRE-DELIRIC for high-risk patients.

Pandharipande et al. (2013) – BRAIN-ICU Study

• Source: New England Journal of Medicine
• Findings: In 821 ICU patients, delirium duration was independently associated with long-term cognitive impairment at 3 and 12 months post-discharge. Over 50% of patients showed cognitive deficits one year later.
• Significance: Established delirium as the leading predictor of post-ICU cognitive decline, driving research into prevention strategies.

Girard et al. (2018) – MIND Trial

• Source: New England Journal of Medicine
• Findings: Randomized trial of haloperidol and ziprasidone for ICU delirium treatment showed no reduction in delirium duration or severity compared to placebo, questioning the routine use of antipsychotics.
• Significance: Shifted focus toward non-pharmacological interventions like the ABCDEF bundle, which improves compliance and reduces delirium incidence.

Schweickert et al. (2009) – Early Mobilization Trial

• Source: The Lancet
• Findings: Early physical and occupational therapy within 72 hours of intubation halved delirium days in ICU patients compared to usual care.
• Significance: Demonstrated that non-pharmacological interventions, like early mobility, are effective in reducing delirium duration, influencing modern ICU protocols.

Kotfis et al. (2021) – Review on Delirium in ICU

• Source: Intensive Care Medicine
• Findings: Emphasized the ABCDEF bundle (Assess pain, Breathing trials, Choice of sedation, Delirium monitoring, Early mobility, Family engagement) as a key strategy to reduce delirium incidence, with >80% compliance linked to better outcomes.
• Significance: Reinforced the importance of bundled care and highlighted the negative impact of COVID-19 on delirium management.

3. Ventilator associated acute lung injury

A definite preventable harm, but one Merv is likely to dwell on. The introduction of gospel lung-protective ventilation strategies change the face of the landscape (low tidal volume ventilation, established by the ARDSNet trial in 2000). A 2022 study using the MIMIC-IV database underscores this progress,

Lung-Protective Ventilation Strategies

• Low Tidal Volume Ventilation: The cornerstone of VALI prevention remains low tidal volume (VT) ventilation (4–6 mL/kg predicted body weight), as established by the ARDS Network trial. Recent studies reinforce its efficacy in reducing barotrauma and volutrauma, with protocols now widely standardized across ICUs.
• Driving Pressure Optimization: Driving pressure (ΔP = plateau pressure – PEEP) has emerged as a critical parameter. Keeping ΔP < 14–15 cmH₂O correlates with lower mortality in ARDS patients. Advanced ventilators now provide real-time ΔP monitoring to guide settings.
• Personalized PEEP Titration: Positive end-expiratory pressure (PEEP) is tailored using techniques like electrical impedance tomography (EIT) or esophageal pressure monitoring to balance alveolar recruitment and overdistension. Trials suggest individualized PEEP reduces VALI compared to fixed PEEP tables.

Advanced Ventilator Modes

• Airway Pressure Release Ventilation (APRV): APRV and its time-controlled adaptive variants promote spontaneous breathing and lung recruitment while minimizing cyclic atelectasis. Recent meta-analyses show APRV may reduce VALI in ARDS by maintaining open lung mechanics.
• Neurally Adjusted Ventilatory Assist (NAVA): NAVA synchronizes ventilation with diaphragmatic electrical activity, improving patient-ventilator interaction. Studies indicate NAVA reduces over-assistance, potentially decreasing diaphragmatic dysfunction and VALI.
• High-Frequency Oscillatory Ventilation (HFOV): While HFOV fell out of favor due to mixed trial results, refined protocols using lower amplitudes and personalized frequencies are being re-evaluated for severe ARDS to minimize VILI.

Extracorporeal Support

• ECMO as a Rescue Therapy: Extracorporeal membrane oxygenation (ECMO) allows ultra-protective ventilation (very low VT and pressures) in severe ARDS, reducing VALI. Advances in ECMO technology (e.g., smaller, more efficient circuits) and better patient selection (e.g., EOLIA trial criteria) have improved outcomes.
• ECCO2R for Hypercapnia Management: Extracorporeal CO2 removal (ECCO2R) devices enable lower VT ventilation in moderate ARDS by managing hypercapnia, reducing the risk of barotrauma. Ongoing trials are refining its role in VALI prevention.

Pharmacologic and Adjunctive Therapies

• Neuromuscular Blockade: Short-term use of neuromuscular blockers (e.g., cisatracurium) in early severe ARDS improves patient-ventilator synchrony, reducing VALI risk. The ROSE trial clarified its targeted use in specific populations.
• Anti-inflammatory Agents: Corticosteroids (e.g., dexamethasone) and other modulators (e.g., IL-6 inhibitors) are being studied to mitigate ventilator-induced inflammation. Small trials suggest reduced lung injury scores with early, low-dose steroids.
• Prone Positioning: Prone ventilation, now standard in severe ARDS (per PROSEVA trial), reduces VALI by improving lung homogeneity and decreasing overdistension in dependent lung regions. Automated proning beds are enhancing feasibility in ICUs.

Monitoring and Diagnostics

• Electrical Impedance Tomography (EIT): EIT provides real-time imaging of regional lung ventilation, enabling precise adjustments to PEEP and VT to avoid overdistension or collapse. Its adoption is increasing in advanced ICUs.
• Lung Ultrasound: Routine lung ultrasound helps detect early signs of VALI (e.g., B-lines, consolidation) and guides ventilation adjustments. Protocols combining ultrasound with clinical data could improve outcomes.
• Biomarkers: Biomarkers like sRAGE, IL-6, and surfactant protein D are being explored to detect early VALI and guide therapy. While not yet standard, they show promise in clinical trials.

Artificial Intelligence and Decision Support

• AI-Driven Ventilation: Machine learning algorithms are being integrated into ventilators to predict optimal settings based on patient physiology and real-time data. Pilot studies suggest AI can reduce VALI by dynamically adjusting parameters to minimize mechanical stress.
• Predictive Analytics: AI models analyzing EHR data, ventilator waveforms, and imaging can predict VALI risk, enabling preemptive adjustments. These tools are in early adoption but show high sensitivity.

Rehabilitation and Post-ICU Care

• Early Mobilization: Protocols for early physical therapy in ventilated patients reduce diaphragmatic weakness and improve long-term lung function, indirectly mitigating VALI effects.
• Diaphragm-Protective Ventilation: Strategies to preserve diaphragmatic function (e.g., partial support modes) are gaining traction to prevent ventilator-induced diaphragmatic dysfunction, a contributor to prolonged VALI recovery.

4. Sepsis

On sepsis treatment, Merv will likely highlight the evolution of standardized protocols that have improved survival rates over the past 40 years. The Surviving Sepsis Campaign, updated in 2021, recommends early goal-directed therapy within 6 hours, including fluid resuscitation, vasopressors for persistent hypotension, and lactate monitoring.

A 2025 study on sepsis in Japan estimates 420,000 annual PICS cases following sepsis, underscoring its long-term impact.

• There’s the withdrawal of starch-based colloids!!
• We have shifted from dopamine to dobutamine, reflecting better evidence on safety and efficacy.
• There are experimental biomarkers of promise and potential. A 2024 pilot study explored METRNL as a potential biomarker, but results are preliminary.
• Let’s face it, there’s a the lack of rapid, accurate diagnostic criteria for sepsis. Merv may advocate for personalized approaches, like using biomarkers to tailor antibiotic therapy. He will no doubt throw caution to the wind on the use of prophylactic antibiotics. A 2020 expert statement from Wuhan found them to be entirely ineffective in preventing secondary infections in COVID-19 patients, for example.

Things We Do That Are Supported by Evidence

Early, Effective Antibiotics

• Evidence Base: Observational data consistently show that timely administration of appropriate antibiotics significantly reduces mortality in sepsis. Studies emphasize the importance of initiating broad-spectrum antibiotics within the first hour of sepsis recognition, particularly in septic shock, where delays increase mortality risk.
• Key Trials and Meta-Analyses: No single randomized controlled trial (RCT) dominates this area due to ethical constraints, but observational studies highlight compelling mortality reductions with early antibiotics. Meta-analyses reinforce this, showing that each hour of delay in antibiotic administration increases mortality by approximately 7-8% in septic shock.
• Impact: This is a cornerstone of the Surviving Sepsis Campaign (SSC) guidelines, widely adopted in clinical practice due to robust, consistent observational evidence.

Prompt Fluid Resuscitation and Source Control

• Evidence Base: Early fluid resuscitation to restore perfusion is still steeped in controversy! But we know that rapid source control (e.g., draining abscesses or removing infected devices) are supported by observational and cohort studies. These interventions improve outcomes by addressing hypoperfusion and eliminating the infection source.
• Key Trials and Meta-Analyses: The FEAST trial (2011) showed that excessive fluid boluses in resource-limited settings could harm children with severe infection, but in high-resource settings, studies like those in the SSC guidelines (2008, 2012) support moderate fluid resuscitation.
• Impact: These remain standard practices, though the optimal fluid volume and type (choice of crystalloids, albumin), remains debatable.

Things That Evidence Did Not Support

Activated Protein C (Drotrecogin Alfa)

• Background: Recombinant human activated protein C (aPC) was initially hailed for its antithrombotic, anti-inflammatory, and profibrinolytic properties, with potential to reduce mortality in severe sepsis.
• Key Trials:
  • PROWESS (2001): This phase 3 RCT (n=1,690) reported a 6.1% absolute mortality reduction (19.4% relative risk reduction, P=0.005) in severe sepsis patients treated with aPC (24 μg/kg/hour for 96 hours) compared to placebo. It led to FDA approval but raised concerns about bleeding risks (3.5% vs. 2% serious bleeding, P=0.06).
  • ADDRESS (2005): This RCT (n=2,639) tested aPC in patients with severe sepsis and lower mortality risk (APACHE II score <25). It was stopped early for futility, showing no mortality benefit and increased bleeding in low-risk patients, particularly those with single-organ dysfunction or recent surgery.
  • PROWESS-SHOCK (2012): A follow-up phase 3 RCT (n=1,697) in septic shock patients found no mortality benefit (26.4% vs. 24.2% at 28 days, RR 1.09, 95% CI 0.92-1.28) and confirmed increased bleeding risk. This trial led to aPC’s withdrawal from the market.
  • RESOLVE (2007): A paediatric trial showed no benefit in children with severe sepsis, further questioning aPC’s efficacy across populations.
• Meta-Analyses:
  • A 2005 meta-analysis of PROWESS and ADDRESS (n=4,329) found no overall mortality benefit (RR 0.92, 95% CI 0.83-1.02), particularly in low-risk patients (APACHE II <25).
  • A 2012 Cochrane review (6 trials, n=6,788) confirmed no significant effect on 28-day mortality (RR 1.00, 95% CI 0.86-1.16) and noted increased bleeding risk (RR 1.67, 95% CI 1.18-2.37).
  • A 2015 Bayesian analysis incorporating observational studies suggested some observational evidence of benefit, but RCTs consistently showed no effect, highlighting the discrepancy between real-world and controlled settings.
• Why It Failed: Inconsistent trial results, unclear mechanisms of action, and significant bleeding risks undermined aPC’s utility. The PROWESS trial’s success may have been influenced by suboptimal usual care (e.g., late antibiotics or poor resuscitation), which improved by the time of PROWESS-SHOCK due to SSC guidelines. Additionally, aPC’s efficacy was limited to the sickest patients, and trials like ADDRESS and PROWESS-SHOCK excluded or failed to replicate benefits in these subgroups.
• Impact: aPC (Xigris) was withdrawn in 2011, prompting reflection on sepsis trial design and the need for better patient selection and mechanistic understanding.

Early Goal-Directed Therapy (EGDT)

• Background: EGDT, introduced by Rivers et al. (2001), aimed to optimize hemodynamics in early septic shock using protocolized resuscitation targeting specific goals (e.g., central venous pressure, mean arterial pressure, and central venous oxygen saturation [ScvO2]).
• Key Trials:
  • Rivers et al. (2001): A single-center RCT (n=263) showed a dramatic mortality reduction (30.5% vs. 46.5%, P=0.009) with EGDT compared to standard care, leading to its inclusion in SSC guidelines.
  • ProCESS (2014): A multicenter RCT (n=1,341) found no mortality benefit of EGDT (21.0%) vs. protocol-based standard therapy (18.2%) or usual care (18.9%) at 60 days (P=0.83).
  • ARISE (2014): A multicenter RCT (n=1,600) showed no difference in 90-day mortality between EGDT (18.6%) and usual care (18.8%, RR 0.98, 95% CI 0.80-1.21).
  • ProMISe (2015): A UK-based RCT (n=1,260) reported no 90-day mortality benefit (29.5% vs. 29.2%, RR 1.01, 95% CI 0.85-1.20) and higher costs with EGDT.
• Meta-Analyses:
  • The PRISM meta-analysis (2017) combined patient-level data from ProCESS, ARISE, and ProMISe (n=3,723) and found no difference in 90-day mortality (RR 0.99, 95% CI 0.88-1.12) or secondary outcomes like ICU stay. Subgroup analyses showed no benefit across patient severity or care settings.
  • A 2015 meta-analysis (10 RCTs, n=4,157) reported no overall mortality benefit (RR 0.93, 95% CI 0.85-1.02) but suggested a benefit in high-mortality settings (>30% control group mortality, RR 0.83, 95% CI 0.72-0.96).
  • A 2016 meta-analysis (5 RCTs, n=4,303) found slight, non-significant mortality reductions at 28, 60, and 90 days (RR 0.85, 95% CI 0.67-1.08), with significant heterogeneity (I2=64%). Benefits were confined to settings with control group mortality >35%.
• Why It Failed: The Rivers trial’s success likely reflected deficiencies in usual care at the time (e.g., delayed fluids or antibiotics), which improved by the 2010s due to SSC guidelines. ProCESS, ARISE, and ProMISe showed that usual care had incorporated many EGDT principles (e.g., early fluids, antibiotics), reducing the incremental benefit of rigid protocols. EGDT’s invasive monitoring (e.g., ScvO2) added complexity and cost without clear advantage, and lactate-guided therapy emerged as a simpler alternative. Added to all of this, most became fluid overloaded, which is almost tantamount to poor blood sugar controls s an effect on overall morbidity and mortality in the critically unwell!
• Impact: EGDT is no longer mandated in SSC guidelines (2016 onwards), which now emphasize early antibiotics, fluids, and lactate monitoring over strict hemodynamic targets. The trials highlighted the importance of general advances in sepsis care over protocolized resuscitation.

Critical Perspective and Future Directions

So, doing more is doing less and one size does not fit all! Its is the simple care and attention we are all trained for, that wins the race here! Oh, and the SSC…of course!

5. PICS

A huge and ever increasing burden for our patients. See our writeup here, will Merv talk along the same lines?

6. Outreach

The ‘Angels of the hospital’, have to get a mention. Early intervention is always the key….Critical care outreach teams are now standard in many hospitals, and have enabled earlier identification of deteriorating patients on general wards. This shift, supported by tools like the National Early Warning Score (NEWS), has reduced ICU admissions by addressing issues before they escalate. A 2023 study in the UK found that outreach teams decreased cardiac arrest rates on wards by 15%, showcasing their impact. Mervyn likely sees this as a cornerstone of modern critical care, allowing for timely interventions that save lives.

Improved Patient Survival and Reduced Mortality

• A non-randomized population-based study conducted in a tertiary referral teaching hospital (2000–2002) found that the introduction of a CCOT improved survival to hospital discharge by 6.8% (risk ratio 1.08) after discharge from critical care. The study also noted a 6.4% reduction in readmissions to critical care, suggesting that CCOTs help stabilize patients during the vulnerable recovery period post-ICU.
• A 2015 meta-analysis of 29 studies (1990–2013) reported that rapid response systems, including CCOTs, were associated with reduced hospital mortality in both adult and paediatric populations. The analysis highlighted a consistent trend toward fewer cardiopulmonary arrests, indicating that early intervention by these teams can prevent severe adverse events.
• A 2021 study noted that CCOTs contribute to timely recognition and management of deteriorating patients, potentially reducing avoidable deaths by ensuring escalation of care when needed.

Reduction in Adverse Events

• Pragmatic studies of METs, which share similarities with CCOTs, have shown reductions in cardiac arrest rates and decreased use of intensive care resources for cardiac arrest survivors. This suggests that CCOTs can prevent deterioration to the point of critical events through early intervention.
• A UK study found that CCOTs increased the issuance of Do Not Attempt Resuscitation (DNAR) orders (moderate-quality evidence), which can prevent unnecessary and distressing interventions for patients with poor prognoses, aligning care with patient preferences.
• A 2019 service improvement project at Whittington Health NHS Trust demonstrated that enhancing CCOT referral processes reduced delays in managing critically ill patients, leading to earlier expert interventions and potentially reducing morbidity.

Support for Timely ICU Admissions and Reduced Readmissions

• CCOTs facilitate timely ICU admissions by identifying deteriorating patients early and initiating appropriate interventions, which can prevent the need for ICU care or ensure it occurs promptly for better outcomes. A 2006 systematic review noted that CCOTs help avoid unplanned ICU admissions by supporting ward staff in managing acutely ill patients.
• In a UK study, patients who received CCOT visits post-ICU discharge had lower hospital mortality and shorter hospital stays compared to those who did not, indicating that CCOTs support recovery and prevent readmissions.
• Australian studies reported that CCOTs (or equivalent liaison nurse services) reduced ICU discharge delays and increased the likelihood of patients receiving higher levels of care when needed, such as surgical interventions.

Enhanced Staff Support and Education

• Qualitative studies have shown that CCOTs provide significant educational support to ward staff, particularly junior nurses, improving their ability to manage critically ill patients. A 2008 Australian study found that ward nurses valued CCOTs as an educational resource, enhancing their confidence and skills in caring for post-ICU patients.
• A 2019 evaluation at a UK hospital reported that 58 out of 195 staff members surveyed (30% response rate) highly valued CCOTs for their accessibility, advice, and role in skill development, which indirectly benefits patients through improved ward care.
• CCOTs improve communication between ICU and ward teams, streamlining patient transitions and reducing stress for staff, which can enhance the quality of care delivered.

Specialised Care for Vulnerable Populations

• In maternal critical care, CCOTs play a vital role in supporting pregnant or postpartum women with complex comorbidities. A 2023 article highlighted that CCOTs help identify deteriorating obstetric patients on general wards, facilitate timely interventions, and provide psychological support, potentially reducing maternal mortality and morbidity.
• CCOTs also support person-centered care by involving patients and families in treatment escalation decisions, such as DNACPR discussions, ensuring care aligns with patient values.

Cost and Resource Efficiency

• A cost-consequences analysis found that rapid response teams, including CCOTs, were associated with 0.0025 fewer cardiac arrests and/or deaths per patient and shorter ICU stays (0.5 days), despite higher costs (£21 more per patient-day). The reduction in critical events and ICU length of stay suggests potential long-term cost savings.
• A UK evaluation noted that CCOTs reduced hospital stays and costs for patients receiving outreach visits post-ICU, as they experienced lower mortality and faster recovery.

But…

• Evidence Gaps: Some studies, such as the MERIT trial in Australia, failed to show significant reductions in ICU admissions or mortality, highlighting variability in CCOT models and challenges in conducting randomized controlled trials due to ethical and practical constraints.
• Heterogeneity: CCOTs vary in composition (nurse-led vs. doctor-led), operational hours, and trigger systems, making it difficult to generalize findings. For example, UK CCOTs are typically nurse-led, while Australian METs are often doctor-led, affecting outcome comparisons.
• Need for Robust Data: While qualitative studies and staff perceptions strongly support CCOTs, quantitative evidence on patient outcomes is sometimes inconsistent or of low to moderate quality, necessitating further research.

7. The MDT

The “Good” aspects of ICU evolution, according to Mervyn, may include the shift toward multidisciplinary and a more holistic approach. ICUs now integrate pharmacists, physiotherapists, and psychologists alongside doctors and nurses to address not just acute illness but also long-term recovery. This approach aligns with the ABCDEF bundle (Awakening and Breathing Coordination, Delirium monitoring, Early mobility, Family engagement), which a 2024 study linked to lower 6-month mortality when fully implemented. Mervyn will likely praised this collaborative model for improving patient outcomes, such as reducing ICU-acquired weakness through early mobilisation—shown in a 2023 study to improve functional outcomes at discharge when done for over 40 minutes daily.

Comprehensive Expertise and Diverse Perspectives

• Why it matters: ITU patients often have multisystem illnesses (e.g., sepsis, acute respiratory distress syndrome, or multi-organ failure) requiring specialized knowledge from various fields.
• MDT benefit: An MDT typically includes intensivists, nurses, respiratory therapists, pharmacists, physiotherapists, dietitians, and sometimes social workers or palliative care specialists. Each member brings unique expertise, ensuring holistic assessment and management.
  • For example, a pharmacist can optimize antimicrobial therapy, while a physiotherapist can address early mobilization to prevent ICU-acquired weakness.
• Sole clinician/nursing limitation: A single clinician or nurse, while skilled, may lack the breadth of knowledge to address all aspects of care, potentially missing critical nuances (e.g., drug interactions or nutritional needs).

Improved Decision-Making and Error Reduction

• Why it matters: ITU care involves high-stakes decisions under time pressure, where errors can be catastrophic.
• MDT benefit: Collaborative decision-making leverages collective knowledge, reducing cognitive bias and oversight. Regular MDT rounds allow for structured discussions, integrating data from monitoring systems, lab results, and clinical observations.
  • Evidence: Studies (e.g., Pronovost et al., 2003) show MDT-led protocols, like those for ventilator-associated pneumonia prevention, reduce morbidity and mortality compared to unilateral decision-making.
• Sole clinician/nursing limitation: A single provider may be prone to tunnel vision or fatigue-driven errors, especially during long shifts, without the checks and balances of team input.

Enhanced Patient-Centered Care

• Why it matters: ITU patients often cannot advocate for themselves, and their families need support to navigate complex care.
• MDT benefit: The team addresses not just medical but also psychological, social, and ethical needs. For instance:
  • Nurses provide continuous bedside monitoring and emotional support.
  • Social workers assist families with decision-making or end-of-life care.
  • Dietitians ensure tailored nutritional support to aid recovery.
  • This holistic approach aligns with patient and family values, improving satisfaction and outcomes.
• Sole clinician/nursing limitation: A single provider may prioritize immediate medical needs over psychosocial or long-term considerations, leading to fragmented care.

Optimized Resource Utilization and Efficiency

• Why it matters: ITU care is resource-intensive, with high costs and limited bed availability.
• MDT benefit: Each team member focuses on their area of expertise, streamlining interventions and avoiding duplication. For example:
  • Pharmacists can de-escalate unnecessary medications, reducing costs.
  • Respiratory therapists optimize ventilator settings, shortening ICU stays.
  • Evidence: MDT-driven protocols, like early goal-directed therapy, have been shown to reduce ICU length of stay and costs, or have they?!
• Sole clinician/nursing limitation: A single provider may lack the time or expertise to optimize all aspects of care, leading to inefficiencies or prolonged recovery.

Continuity and Coordination of Care

• Why it matters: ITU patients require 24/7 monitoring and frequent care plan adjustments.
• MDT benefit: The team ensures seamless handovers and coordinated care plans. Daily MDT rounds standardize communication (e.g., using tools like SBAR—Situation, Background, Assessment, Recommendation), reducing miscommunication.
  • For example, nurses can flag subtle changes in patient status, prompting timely interventions from physicians or specialists.
• Sole clinician/nursing limitation: Without a team, care may be disjointed during shift changes, and critical information may be missed, delaying interventions.

Staff Support and Reduced Burnout

• Why it matters: ITU work is emotionally and physically demanding, with high burnout rates among clinicians and nurses.
• MDT benefit: Shared responsibility distributes workload and emotional burden. Team members support each other, fostering resilience and improving morale.
  • For instance, debriefing sessions after critical events, involving psychologists or chaplains, can mitigate stress.
• Sole clinician/nursing limitation: A single provider may feel isolated, overwhelmed, or unsupported, leading to burnout and compromised care quality.

Evidence-Based and Standardized Care

• Why it matters: Consistency in care improves outcomes in critical care settings.
• MDT benefit: Teams implement evidence-based protocols (e.g., sepsis bundles, delirium prevention) and monitor adherence collaboratively. Regular audits and feedback loops ensure quality improvement.
  • Example: MDT-led checklists for central line insertions significantly reduce infection rates
• Sole clinician/nursing limitation: Individual providers may deviate from best practices due to lack of oversight or awareness, leading to variability in care.

8. Technology

Mervyn loves a bit of tech! He may site this as a “Good” advancement, citing innovations like continuous pulse oximetry, advanced hemodynamic monitoring, and emerging tools like EEG-based delirium detection. A 2024 study suggested that EEG monitoring could enable earlier delirium interventions, though Merv note that such technologies still need validation against bedside assessments like the CAM-ICU. However, he raised a significant “Not-So-Good” consequence of technology: the rise of Electronic Health Records (EHRs). While EHRs have streamlined documentation, Merv might argue they’ve pulled doctors away from the bedside, leading to a disconnect from patient physiology. Doctors now spend up to 40% of their time on administrative tasks, according to a 2023 survey, often prioritising screens over stethoscopes—a trend the Prof may see as detrimental to hands-on care.

1. Artificial Intelligence (AI) and Machine Learning (ML) for Predictive Analytics
   • Description: AI and ML algorithms analyze vast amounts of ICU data (vital signs, lab results, imaging) to predict patient outcomes, detect deterioration early, and guide personalized treatment. Examples include predicting septic shock, mortality risk, and optimal ventilator settings.
   • Promise: These systems can reduce mortality by enabling early interventions (e.g., 17% mortality reduction in septic shock prediction), optimize resource allocation, and support clinical decision-making in high-pressure environments.
   • Applications:
     • Septic Shock Prediction: KAIST’s MediGraph-Net2 uses wearable IoT data and graph neural networks to predict septic shock six hours earlier than standard protocols.
     • Outcome Prediction: An AI model predicts ICU patient outcomes with 92% accuracy by day five, identifying key mortality risk biomarkers.
     • Sepsis Diagnosis and Discharge Planning: AI algorithms assist in diagnosing sepsis and identifying patients ready for discharge, reducing ICU stays.
2. Tele-ICU and Remote Monitoring (eICU)
   • Description: Tele-ICU systems use advanced software, high-definition video, and real-time data to allow intensivists to monitor patients remotely from centralized command centers. Systems like NewYork-Presbyterian’s eICU® enable 24/7 oversight across multiple hospitals.
   • Promise: Tele-ICU addresses shortages of ICU specialists, reduces medical errors, shortens hospital stays, and lowers costs by enabling proactive interventions. Studies show lower mortality rates and shorter ICU stays with telemedicine.,
   • Applications:
     • Real-Time Monitoring: eICU platforms track vital signs, ventilators, and lab results, using smart alarms to detect critical events early.
     • Multidisciplinary Care: Seoul National University Bundang Hospital’s eICU facilitates collaboration among specialists for infectious disease patients, reducing staff burden.
3. Point-of-Care (POC) Diagnostic and Imaging Devices
   • Description: Compact, portable devices like handheld ultrasounds and POC haemoglobin analysers provide rapid diagnostics at the bedside, minimising infection risks and delays.
   • Promise: These devices improve timely monitoring, reduce morbidity, and are cost-effective, especially in resource-limited settings. For example, handheld ultrasounds were critical during COVID-19 for safe imaging.
   • Applications:
     • Handheld Ultrasounds: Used for real-time imaging in ICUs, particularly in low- and middle-income countries (LMICs).
     • Hemoglobin and Pulse Oximetry: A University of Texas at Arlington device measures hemoglobin levels accurately at the bedside.
4. Advanced Patient Monitoring Systems
   • Description: Multi-parameter monitors (e.g., aXcent medical’s CETUS x12) and SaaS platforms (e.g., Vigocare’s Vigo Vitals) track vital signs in real time, using AI to detect deviations and support clinical decisions.
   • Promise: These systems consolidate monitoring, reduce staff workload, and enable early detection of deterioration, improving patient outcomes in busy ICUs.
   • Applications:
     • CETUS x12: Features 12-lead ECG, arrhythmia analysis, and pacemaker detection for comprehensive monitoring.
     • Vigo Vitals: Integrates with wireless devices to provide proactive decision support via algorithms.
5. 5G-Enabled Smart ICUs
   • Description: 5G technology supports real-time data transmission for smart wards, enabling remote robotic surgery, expert consultations, and IoT device integration.
   • Promise: High-speed, low-latency 5G enhances interactivity, allowing remote adjustments to equipment and real-time condition monitoring, potentially transforming ICU efficiency. However, its full benefits require further validation.,
   • Applications:
     • Remote Guidance: 5G enables experts to guide complex procedures remotely.
     • IoT Integration: Supports real-time data from multiple devices for intelligent prediction and alarms.
6. Augmentative and Alternative Communication (AAC) Tools
   • Description: Low- and high-tech AAC tools, like communication boards and electronic devices, help mechanically ventilated patients communicate with staff and families.
   • Promise: AAC tools improve patient-centered care, reduce stress, and enhance outcomes by addressing communication barriers. They are particularly effective in resource-limited settings.
   • Applications:
     • Communication Boards: Used in Sri Lankan ICUs to facilitate patient-nurse interactions.
     • Electronic AAC: Customizable tools improve engagement despite initial staff concerns about workflow integration.
7. Electronic ICU Diaries
   • Description: Digital diaries integrated into electronic health records (EHRs) allow families and staff to record daily events, reducing stress and aiding patient recovery.
   • Promise: These diaries mitigate psychological trauma, improve family engagement, and may become standard in EHR systems, enhancing patient-centered care.
   • Applications:
     • Kaiser Permanente’s Prototype: An electronic diary exported to medical records, accessible via patient portals, showed high acceptability.
8. Frugal Innovations for Resource-Limited Settings
   • Description: Low-cost technologies, such as AI-based monitoring systems (<$300 per ICU room) and reusable ventilatory devices, address ICU challenges in LMICs.
   • Promise: These innovations expand ICU capacity, reduce costs, and improve care quality in constrained environments, with potential global applicability.,
   • Applications:
     • AI Monitoring: Sensing technology with AI monitors patients at a fraction of traditional costs.
     • Frugal Ventilators: Designed for durability in extreme conditions, with user-friendly interfaces.

9. Audit

We love to hate these!!! What will Mervyn discuss?

Notably, systematic data collection has driven quality improvement in ICUs. Regular audits, like those conducted by the UK’s Intensive Care National Audit & Research Centre (ICNARC), have identified gaps in care, such as variations in ventilator settings, and spurred standardized protocols. A 2024 ICNARC report showed that hospitals using audit data to refine practices saw a 10% reduction in ICU mortality over five years. So, here are some that have catalysed or introduced enhanced evidence based care:

ICNARC Case Mix Programme (CMP) Enhancements

The Intensive Care National Audit and Research Centre (ICNARC) in the UK continues to lead with its Case Mix Programme (CMP), which audits patient outcomes in adult critical care units. Recent innovations include:

• Real-Time Data Reporting: ICNARC’s 2025 strategy emphasizes quarterly Quality Reports (QQR) with faster data turnaround, enabling critical care units to act on quality indicators like sepsis management and infection rates promptly. Over 2.8 million patient records are analyzed, providing robust benchmarking against national standards.
• Patient-Centered Metrics: The CMP now incorporates Patient-Reported Experience Measures (PREMs) and Patient-Reported Outcome Measures (PROMs), aligning audits with patient experiences to ensure holistic care quality assessment.
• Focus on Non-Clinical Transfers: Audits highlight issues like bed capacity by tracking non-clinical transfers, which can increase patient risk and prolong stays. Units in the bottom 5% for delayed discharges are flagged for quality improvement.

ICNARC Case Mix Programme

Irish National ICU Audit (INICUA)

The Irish National ICU Audit (INICUA), managed by the National Office of Clinical Audit (NOCA), is a quality and safety initiative benchmarking Irish ICUs against international standards. Key innovations in 2025 include:

• Comprehensive Coverage: The 2022 report (latest available) covered 96% of Level 3 ICU care in 22 public hospitals, auditing 11,008 admissions. The 2025 audit expands to include pediatric critical care via the Irish Paediatric Critical Care Audit (IPCCA).
• Quality Improvement Initiatives: Data-driven interventions, such as reducing ventilator-associated pneumonia, are informed by audit findings. Professor Rory Dwyer, INICUA’s Clinical Lead, presented these at ICNARC’s 2025 CMP Annual Meeting, emphasizing local hospital improvements.
• Public and Patient Involvement (PPI): A former ICU patient chairs the governance committee, ensuring audits reflect patient priorities, a novel approach to stakeholder engagement.

NOCA Irish National ICU Audit

Integration of AI and Technology in Audits (More above)

Technology is transforming ICU audits, with AI and digital tools streamlining data collection and analysis:

• AI-Powered Solutions: Posts on X highlight AI-driven platforms optimizing ICU care by automating data aggregation and identifying care gaps in real time. These tools address staffing shortages and high-pressure environments by prioritizing actionable insights.
• MyAudit Tool: Developed by Global View, MyAudit aligns with the UK’s 2021 National Standards of Healthcare Cleanliness (updated for 2025). It digitizes auditing for infection control, offering compliance tracking and public-facing cleanliness ratings, critical for ICU safety.
• InPhase Audit Oversight: InPhase’s platform simplifies clinical audits by triangulating data for patient safety. It supports the 2025 CMS Patient Safety Structural Measure (PSSM), reducing manual workload and enabling rapid action on audit findings.

Here are some handy links!

• MyAudit Tool
• InPhase Clinical Audits
• X Post on AI in ICUs

Quality Indicators and Standardised Bundles

The Royal College of Anaesthetists’ Audit Recipe Book (ARB) and the Faculty of Intensive Care Medicine (FICM) have introduced standardized audit bundles for 2025:

• Core Audit Topics: These include central venous catheter bloodstream infection (CVCBSI) rates and compliance with insertion bundles. Audits now mandate active surveillance, standardizing CVC packs across regions to reduce infections.
• Collaborative Benchmarking: Standardized methodologies allow regional and national comparisons, fostering collaboration among ICUs. The ARB’s 16 ICU audits emphasize evidence-based benchmarks, ensuring measurable improvements in patient outcomes.

Improving Quality in ICU through Clinical Audit

CMS Hospital Inpatient Quality Reporting (IQR) Program Updates

In the US, the Centers for Medicare & Medicaid Services (CMS) IQR program for 2025 introduces audit innovations for ICUs:

• Dual Validation Scoring: Starting in 2025, audits assess both clinical processes of care (CPoC) and electronic Clinical Quality Measures (eCQMs) with equal weight (50% each). A 75% accuracy threshold for eCQMs ensures data reliability.
• Patient-Reported Outcomes: The new Total Hip Arthroplasty/Total Knee Arthroplasty Patient-Reported Outcome-Based Performance Measure (THA/TKA PRO-PM) integrates patient input, a first for ICU-relevant audits, enhancing care personalization.
• Data Submission: Hospitals must submit data via the Hospital Quality Reporting (HQR) system by May 15, 2025, with public reporting on Care Compare, increasing transparency.

CMS 2025 IQR Requirements

6. Clinical Audit Conference 2025

The Clinical Audit Conference 2025, hosted by Government Events, emphasizes innovative auditing practices:

• Patient-Reported Outcomes Integration: Audits now incorporate patient experiences, providing a comprehensive view of care quality.
• Blame-Free Culture: The conference promotes learning from negative findings, encouraging continuous improvement without punitive measures.
• Networking and Best Practices: It facilitates collaboration among audit leads and policymakers, sharing case studies like the Sentinel Stroke National Audit Programme (SSNAP), which informs ICU stroke care.

Clinical Audit Conference 2025

10. Anarchy!

While anarchy traditionally refers to the absence of hierarchical authority, in this case, it could describe situations where protocolled care—intended to standardise and improve patient outcomes—leads to chaotic or suboptimal results due to inflexibility, misapplication, or systemic failures.What could our eminent professor talk about in the context go ICU then?

Over-Reliance on Protocols Leading to Reduced Clinical Judgment

• Issue: Protocolled care, designed to standardize treatment (e.g., for sepsis, mechanical ventilation, or sedation), can sometimes stifle clinical judgment. Clinicians may feel compelled to follow protocols even when patient-specific factors suggest deviation, leading to inappropriate care and chaotic outcomes.
• Example: Studies on sepsis management, such as early goal-directed therapy (EGDT), initially protocolized in the Surviving Sepsis Campaign, showed mixed results. Later trials (e.g., ARISE, ProCESS) found that strict adherence to EGDT did not consistently improve outcomes compared to individualized care, suggesting protocols can create confusion when applied universally.
• Consequence: This rigidity can lead to a form of “anarchy” where the protocol becomes the de facto authority, undermining the expertise of intensivists and causing disorganized care delivery when protocols fail to address complex cases.
• Reference:
  • Rivers et al., Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock
  • Rowan et al., Early, Goal-Directed Therapy for Septic Shock—A Patient-Level Meta-Analysis

2. Heterogeneity in Protocol Implementation Across Global ITUs

• Issue: Protocols are often developed based on high-resource settings but applied globally, including in resource-limited settings, leading to inconsistent application. This creates disparities in care quality, resembling a lack of unified governance or “anarchy” in global ITU standards.
• Example: A survey on pediatric critical care highlighted significant differences in resources and practices between resource-rich and resource-limited countries, affecting protocol adherence (e.g., for sepsis or ventilation). Protocols like low tidal volume ventilation (LTV) for ARDS are underutilized in some regions due to lack of training or equipment, leading to variable outcomes.
• Consequence: The uneven application of protocols can result in chaotic care delivery, with some patients receiving substandard treatment due to systemic barriers, undermining the intended order of protocolled care.
• Reference:
  • Tripathi et al., A Survey on the Resources and Practices in Pediatric Critical Care
  • 21st Century Critical Care Medicine: An Overview

Protocol Overload and Staff Burnout

• Issue: The proliferation of protocols (e.g., for sedation, delirium prevention, or antibiotic stewardship) can overwhelm ITU staff, especially during crises like the COVID-19 pandemic. This leads to protocol fatigue, where staff struggle to comply, resulting in disorganized care delivery.
• Example: During COVID-19, rapid protocol changes for ventilation, anticoagulation, and immunomodulatory therapies (e.g., tocilizumab) created confusion. A study noted that ICU teams faced “vulnerability and loss of control” due to frequent protocol shifts and resource constraints, resembling a chaotic work environment.
• Consequence: Overburdened staff may bypass protocols or apply them inconsistently, leading to a breakdown in standardized care—an anarchic state where protocols exist but are not effectively followed.
• Reference:
  • Intensive Care Management of Patients with COVID-19: A Practical Approach
  • The Positive Impact of COVID-19 on Critical Care

Iatrogenic Harm from Rigid Protocols

• Issue: Protocols can inadvertently cause harm when applied without flexibility, contributing to iatrogenic complications (e.g., ventilator-associated pneumonia, delirium, or antibiotic resistance). This creates a paradoxical situation where protocols, meant to ensure order, lead to adverse outcomes.
• Example: Sedation protocols using continuous infusions rather than intermittent boluses have been linked to increased delirium risk in ICU patients, with up to 80% of critically ill patients affected. Similarly, procalcitonin-guided antibiotic protocols reduced overuse but showed inconsistent mortality benefits, raising concerns about blanket application.
• Consequence: The resulting complications disrupt patient care continuity, creating a chaotic cycle of managing protocol-induced harms, akin to anarchy in clinical outcomes.
• Reference:
  • Delirium in the Intensive Care Unit
  • Procalcitonin-Guided Antibiotic Therapy in Intensive Care Unit Patients

Conflict Between Protocols and Patient-Centered Care

• Issue: Protocols often prioritize population-level outcomes over individual patient needs, clashing with the principles of patient-centered care. This tension can lead to distrust among patients, families, and staff, fostering a sense of disorder in the ITU environment.
• Example: The ABCDEF bundle (for ICU liberation) emphasizes protocolized steps to reduce sedation and promote early mobility. However, its application in pediatric or neurologically impaired patients can be challenging, leading to inconsistent care. Similarly, anarchist principles, which emphasize autonomy and non-hierarchical care, highlight how protocols can alienate patients by reducing their agency.
• Consequence: This conflict can create a fragmented care experience, where patients and families feel protocols override their needs, resembling an anarchic disconnect between care providers and recipients.
• Reference:
  • A Review of Key Strategies to Address the Shortage of Analgesics and Sedatives in Pediatric Intensive Care
  • Anarchy and Its Overlooked Role in Health and Healthcare

Anarchist Perspectives on Protocolled Care

• Issue: From an anarchist viewpoint, protocolled care can be seen as inherently hierarchical, imposing top-down rules that suppress clinician and patient autonomy. This aligns with anarchist critiques of centralized authority, suggesting protocols create a form of “soft anarchy” by fostering resistance or non-compliance among staff and patients.
• Example: Historical examples like the Peckham Health Centre (1930s) operated on anarchist principles of mutual aid and autonomy, contrasting with state-driven protocolled care. Modern mutual aid groups during COVID-19 similarly bypassed rigid protocols to provide community-based care, highlighting how protocolled systems can alienate communities.
• Consequence: Resistance to protocols can lead to decentralized, ad-hoc care practices, creating a chaotic patchwork of care delivery that defies the intended order of standardization.
• Reference:
  • Anarchy and the NHS: How Can Radical Politics Bring a New Perspective to Health and Care?
  • Health and Welfare: Rejecting the State in the Status Quo

7. Technological and AI-Driven Protocols Exacerbating Chaos

• Issue: The integration of artificial intelligence (AI) and machine learning into ICU protocols (e.g., for sepsis prediction or ventilation settings) introduces complexity and reproducibility issues. Lack of clear protocols for AI validation can lead to inconsistent application, creating a form of technological anarchy.
• Example: A study on AI mortality prediction models using the MIMIC-III database found significant reproducibility issues, with half the experiments showing large sample size differences. This undermines trust in AI-driven protocols, leading to erratic adoption.
• Consequence: The reliance on unproven or poorly standardized AI tools can disrupt clinical workflows, resulting in chaotic decision-making processes that deviate from evidence-based care.
• Reference:
  • Artificial Intelligence in Critical Care Medicine

11. Negative studies

Many recent studies in critical care medicine were anticipated to change clinical practice, but did not yield the expected positive results. We seem to live in a world where the negative trial dominates. Are we striving for ‘over-positivity’? There are so many we could pick on, what could Merv discuss? I have picked a couple as examples:

Negative Aspects of Negative Trials in ICU

1. Missed Opportunities for Improved Care
   Negative trials test interventions expected to improve critical outcomes, such as mortality or recovery time. When they fail, patients lose potential benefits. For example, the ACTT-2 trial (2020) found that baricitinib plus remdesivir reduced recovery time in COVID-19 patients but did not significantly lower mortality, disappointing hopes for a game-changing therapy in severe cases.
   • Link: Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19
2. Resource and Time Wastage
   Large ICU trials require significant resources, including funding, staff, and patient recruitment. Negative results, like those from the ACTT-2 trial, mean these resources might have been better directed elsewhere, delaying progress in finding effective treatments for critically ill patients.
3. Clinician and Patient Disappointment
   Negative findings can frustrate ICU teams and patients’ families who anticipate new solutions. The ACTT-2 trial’s lack of mortality benefit for baricitinib (2020) dampened enthusiasm for immunomodulatory therapies in COVID-19, potentially reducing confidence in similar research efforts.
4. Potential Harm from Early Adoption
   Before trial results are confirmed, some ICUs may adopt interventions based on early promise. Negative trials, like the SOS-Ventilation trial (no benefit from immediate sedation interruption, 2017), reveal that such practices may be ineffective or harmful, requiring a return to standard care and posing risks to patients in the interim.
   • Link: Immediate Interruption of Sedation in Critically Ill Postoperative Patients

Positive Aspects of Negative Trials in ICU

1. Preventing Harmful Practices
   Negative trials protect patients by identifying ineffective or potentially harmful interventions. The ACTT-2 trial’s finding that baricitinib didn’t reduce mortality (2020) prevented its overuse in ICU settings, ensuring resources focus on therapies with proven benefits.
2. Refining Clinical Practice
   Negative results clarify what doesn’t work, streamlining ICU protocols. For instance, the PERSONALIZED ARDS trial (2021) showed personalized ventilation didn’t outperform standard low-tidal-volume ventilation, reinforcing the latter’s role and reducing unnecessary variations in care.
   • Link: Personalized Mechanical Ventilation in ARDS
3. Guiding Future Research
   Negative trials highlight areas for further study. The ACTT-2 trial’s neutral mortality outcome (2020) suggested that baricitinib’s benefits might be limited to specific patient groups, prompting research into targeted immunomodulation strategies for severe COVID-19.
4. Improving Trial Design and Patient Selection
   Negative trials often expose design flaws, such as patient misclassification (e.g., 21% in the PERSONALIZED ARDS trial). These insights lead to better inclusion criteria and study methodologies, improving the reliability of future ICU research.
5. Advancing Evidence-Based Medicine
   By rigorously testing hypotheses, negative trials strengthen the evidence base. The SOS-Ventilation trial (2017) showed immediate sedation interruption wasn’t universally beneficial, promoting individualised sedation strategies and ensuring ICU care remains data-driven.

Negative ICU trials can be discouraging, as they delay breakthroughs and consume resources, but they are critical for patient safety and scientific advancement. They prevent the adoption of ineffective treatments, refine clinical and research approaches, and uphold evidence-based medicine. In the high-stakes ICU, where precision is vital, negative trials like ACTT-2 ensure only effective interventions reach patients while guiding smarter future studies.

12. The firm!

Another poignant “Not-So-Good” consequence Mervyn may address, is the loss of the ‘firm’ structure and ‘love’ amongst colleagues in medicine. The traditional firm model, where teams worked closely under a senior consultant, fostered camaraderie and mentorship. Today’s shift-based systems, while improving work-life balance, have eroded these bonds, leaving many clinicians feeling isolated

This is perhaps far less of an issue within the 4 walls of ICU, but it is definitely an issue out there on the wards! Many of our trainees, who are non-anaesthesia based, may be coming directly out of this sort of environment. So, we need to foster and nurture them…similarly, we don’t want to be over-sickly regarding the far more stable team based environment within the ‘Ivory Tower’ of ICU. Sending them back after their ICU rotations full of dread, is not the aim! With knowledge of the isolation out there, a sympathetic ear is needed when in receipt of a less than decent referral. They have probably been juggling far too many plates out there, are seeing them drop around them, with little backup!

Summary

Merv is likely to leave us all thinking about where we have been, and where we are today. Hopefully, we will get a balanced perspective: immense pride in ICU advancements like reduced iatrogenic harm, earlier interventions, and multidisciplinary care, but also a sobering recognition of challenges like protocol-driven antibiotic overuse, the pitfalls of EHRs, and the loss of collegial bonds. He is likely to emphasise the mantra of personalised, human-centered approaches to critical care; one that leverages technology and audits, without losing sight of the bedside and the team spirit that once defined medicine.

See you at SOA25!

JW